Yoshie Umemura
Adjunct Clinical Assistant Professor of Neurology
[email protected]

Available to mentor
Yoshie Umemura
Adjunct Clinical Assistant Professor
  • Recent Publications
    • Recent Publications See All Publications
    • Journal Article
      CTNI-19. MYCOPHENOLATE MOFETIL TARGETS GLIOBLASTOMA DE-NOVO PURINE METABOLISM TO OVERCOME CHEMORADIATION RESISTANCE IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
      Umemura Y, Clarke N, Al-Holou W, Elaimy A, Scott A, Leung D, Kim M, Ferris S, Thomas J, Heth J, Schipper M, Suresh K, Lawrence T, Wahl D. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii99 - viii100. DOI:10.1093/neuonc/noae165.0386
    • Journal Article
      CTNI-50. CLINICAL EFFICACY AND PK/PD RESPONSE IN A PHASE 0/2 STUDY OF NIRAPARIB PLUS RADIOTHERAPY FOR NEWLY-DIAGNOSED, MGMT-UNMETHYLATED GLIOBLASTOMA
      Sanai N, Umemura Y, Margaryan T, Molloy J, Zhang H, Knight W, Harmon J, Hong A, Wanebo J, Braun K, Kennedy WR, Garcia M, Barani I, Yoo W, Tien A-C, Tovmasyan A, Mehta S. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii107 - viii108. DOI:10.1093/neuonc/noae165.0417
    • Journal Article
      CTNI-51. A PHASE 0/1 STUDY OF BDTX-1535 IN RECURRENT GLIOBLASTOMA (GBM) PATIENTS WITH EGFR ALTERATIONS OR FUSIONS
      Sanai N, Umemura Y, Karapetyan V, Margaryan T, Huttenlocher D, Harmon J, Hong A, Yoo W, Tien A-C, Tovmasyan A, Mehta S. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii108 - viii108. DOI:10.1093/neuonc/noae165.0418
    • Journal Article
      CTNI-55. A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN NEWLY DIAGNOSED, MGMT-UNMETHYLATED AND RECURRENT GLIOBLASTOMA PATIENTS
      Sanai N, Umemura Y, Desai S, Margaryan T, Molloy J, LoCascio C, Elliott M, Harmon J, Hong A, Melendez EL, Wanebo J, Braun K, Kennedy WR, Garcia M, Yoo W, Tovmasyan A, Tien A-C, Mehta S. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii109 - viii109. DOI:10.1093/neuonc/noae165.0422
    • Journal Article
      CTNI-58. A PHASE 0/2 TRIAL OF ABEMACICLIB PLUS LY3214996 IN RECURRENT GLIOBLASTOMA
      Sanai N, Umemura Y, Chang Y-W, Margaryan T, DeSantis A, Elliott M, Molloy J, Huttenlocher D, Hook G, Yoo W, Tien A-C, Tovmasyan A, Mehta S. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii110 - viii110. DOI:10.1093/neuonc/noae165.0425
    • Journal Article
      QLTI-03. REAL-WORLD PARADIGM FOR TREATMENT OF PRIMARY CNS LYMPHOMA PATIENTS IN CLINICAL PRACTICE
      Umemura Y, Nayak L, Nijland M, Mohile N, Batchelor T, Strowd R. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii257 - viii257. DOI:10.1093/neuonc/noae165.1018
    • Journal Article
      JS02.5.A A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN RECURRENT GLIOBLASTOMA PATIENTS
      Sanai N, Umemura Y, Desai S, Margaryan T, Molloy J, Cascio CL, Elliott M, Harmon J, Hong A, Melendez EL, Wanebo J, Braun K, Kennedy W, Garcia M, Yoo W, Tovmasyan A, Tien A, Mehta S. Neuro-Oncology, 2024 Oct 17; 26 (Supplement_5): v8 - v8. DOI:10.1093/neuonc/noae144.021
    • Journal Article
      OS06.9.A A PHASE 0/1 ‘TRIGGER’ TRIAL OF BDTX-1535 IN RECURRENT HIGH-GRADE GLIOMA (HGG) PATIENTS WITH EGFR ALTERATIONS OR FUSIONS
      Sanai N, Umemura Y, Karapetyan V, Margaryan T, Huttenlocher D, Harmon J, Hong A, Yoo W, Tien A, Tovmasyan A, Mehta S. Neuro-Oncology, 2024 Oct 17; 26 (Supplement_5): v22 - v22. DOI:10.1093/neuonc/noae144.064